Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.
This phase II clinical trial investigates a one-time oromucosal dose of tetrahydrocannabinolcannabidiol (THCCBD) in 23 patients with indolent leukemic B cell lymphomas. Primary endpoint was a significant reduction in leukemic B cells. Grade 1 - 2 adverse events were seen in 91% of the patients most common were dry mouth (78%), vertigo (70%), and somnolence (43%). After THCCBD a significant reduction in leukemic B cells (median, 11%) occurred within two hours (